Gamida Cell (Gamida Cell) Margin of Safety % (DCF Earnings Based) : N/A (As of Apr. 29, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Gamida Cell Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Gamida Cell's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of Gamida Cell's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, Gamida Cell's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Gamida Cell's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gamida Cell's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Gamida Cell's Margin of Safety % (DCF Earnings Based) falls into.

Gamida Cell Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of Gamida Cell's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Gamida Cell (Gamida Cell) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gamida Cell Ltd (OTCPK:GMDAQ) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116

Website

https://www.gamida-cell.com

Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.

Executives

Jeremy Blank	director	6446 DREXEL AVENUE, LOS ANGELES CA 90048
Mary Theresa Coelho	officer: Chief Financial Officer	52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Ronit Simantov	officer: CMO & Chief Scientific Officer	1988 CHAPEL STREET, NEW HAVEN CT 06515
Abigail L. Jenkins	director, officer: President and CEO	C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116
Stephen T Wills	director	PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ivan M. Borrello	director	C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Anat Cohen-dayag	director	C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Naama Halevi-davidov	director	C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003
Joshua F. Patterson	officer: General Counsel	C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bio Medical Investment (1997) Ltd.	other: Affiliate of 10% Owner	3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301
Shai Lankry	officer: Chief Financial Officer	C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Ai Gamida Holdings Llc	other: Affiliate of 10% Owner	40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ofer Gonen	director	1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Clal Biotechnology Industries Ltd.	other: Affiliate of 10% Owner	3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik	10 percent owner	C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019